'Preclinical development' diaporamas de présentation

An Overview of the NCI SBIR Program

701 views • 43 slides

Value Assessment of Development-Stage Assets Pharmaceutical Products, Medical Devices, and Related Intellectual Property

Value Assessment of Development-Stage Assets Pharmaceutical Products, Medical Devices, and Related Intellectual Property. Frank S. Castellana, M.D., Eng.Sc.D. Knollwood Partners, LLC. Objectives.

549 views • 31 slides

The proceeds of the Rights Offering will enable us to:

Handelsbanken lunch meeting Monday 29 March 2010 Presented by Ron Long, CEO Bertil Samuelsson, VP Discovery & Research Rein Piir, CFO / IR. The proceeds of the Rights Offering will enable us to:.

449 views • 31 slides

524 views • 31 slides

The proceeds of the Rights Offering will enable us to:

Handelsbanken lunch meeting Monday 29 March 2010 Presented by Ron Long, CEO Bertil Samuelsson, VP Discovery & Research Rein Piir, CFO / IR. The proceeds of the Rights Offering will enable us to:.

313 views • 31 slides

Pharmacology/Toxicology information to submit an IND for an anticancer drug

Pharmacology/Toxicology information to submit an IND for an anticancer drug. dr shabeel pn. This presentation is not an official FDA guidance or policy statement. No official support or endorsement by the FDA is intended or should be inferred.

468 views • 27 slides

Kate Morrow, PhD Senior Research Scientist, The Miriam Hospital Associate Professor:

387 views • 25 slides

The Biotechnology Paradigm. Challenges and Opportunities in Latin American Countries Graciela E. Gutman CEUR-CONICET

404 views • 24 slides

Critical Path Initiatives

Critical Path Initiatives. Patricia Keegan, M.D. Center for Drug Evaluation and Research FDA . Pitfalls in Drug Development. Drug Development: changing landscape Critical Path Initiatives FDA analysis of drug development programs. Approach to Review of Drug Development Programs.

314 views • 18 slides

You, Us and Dataseam Making a Difference in Kentucky A Big Difference

334 views • 15 slides

ICARE Member Reports

ICARE Member Reports Epilepsy Therapy Project Joyce Cramer, President Mission: Accelerating ideas into new therapies for people with epilepsy ETP seeks to improve incentives and encourage commercial investment in new therapies. (Treatments reach patients only by commercial routes)

1.27k views • 5 slides

Table_1_Gate_2_criteria

Table 1: GATE 2. Advancing a Vaccine Candidate from Preclinical Development to Early Clinical Stage (Phase I/ IIa ) (2.1 Pathway to GMP Manufacturing and pre-clinical toxicology).

106 views • 1 slides